MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.3 USD | -0.42% |
|
+0.99% | +17.65% |
| May. 02 | Merck: encouraging results in gastric cancer | CF |
| May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
Financials (USD)
| Sales 2024 * | 64.11B | Sales 2025 * | 68.6B | Capitalization | 326B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B | Net income 2025 * | 22.26B | EV / Sales 2024 * | 5.38 x |
| Net Debt 2024 * | 18.91B | Net Debt 2025 * | 7.6B | EV / Sales 2025 * | 4.87 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
14.4
x | Employees | 71,000 |
| Yield 2024 * |
2.38% | Yield 2025 * |
2.51% | Free-Float | 70.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | -0.42% | ||
| 1 week | +0.99% | ||
| Current month | -0.74% | ||
| 1 month | -2.08% | ||
| 3 months | +1.49% | ||
| 6 months | +24.71% | ||
| Current year | +17.65% |
1 week
127.80
132.20
1 month
124.50132.80
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 215 M€ | +11.03% | - | |
| 5.61% | 18 M€ | +3.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 128.3 | -0.42% | 7,405,993 |
| 24-05-01 | 128.8 | -0.33% | 5,895,807 |
| 24-04-30 | 129.2 | -0.69% | 6,944,968 |
| 24-04-29 | 130.1 | -0.82% | 6,829,373 |
| 24-04-26 | 131.2 | +0.37% | 7,758,230 |
Delayed Quote Nyse, May 02, 2024 at 04:00 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
128.3
USD
Average target price
141.6
USD
Spread / Average Target
+10.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.65% | 326B | |
| +29.68% | 699B | |
| +25.07% | 571B | |
| -4.35% | 364B | |
| +3.77% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.79% | 154B | |
| -3.34% | 149B |
- Stock Market
- Equities
- MRK Stock
